C9098 – Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

HCPCS Level II code · C codes: Outpatient PPS (Hospital Outpatient)

Discontinued September 30, 2022 Carrier judgment

HCPCS codeC9098
Long description
Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Short description
Ciltacabtagene car pos t
Pricing indicator
53 Statute
Medicare coverage
C Carrier judgment – coverage decided by the Medicare contractor
BETOS category
O1D Chemotherapy
Added
July 1, 2022
Last change
October 1, 2022 – No change
Termination date
September 30, 2022

Frequently asked questions

What is HCPCS code C9098?

C9098 is a HCPCS Level II code for ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose. It was discontinued on September 30, 2022.

Does Medicare cover C9098?

The HCPCS file lists coverage code C: Carrier judgment – coverage decided by the Medicare contractor. Coverage and payment also depend on local coverage determinations and the patient’s plan.

Nearby C codes

Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.